Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on December 5, 2016, reporting events occurring on November 30, 2016. The company, incorporated in Delaware and headquartered in Ashdod, Israel, entered into a Securities Purchase Agreement with accredited investors to raise capital through the issuance of preferred stock and warrants.
Key Financial Metrics
Capital Raised: The company received aggregate gross proceeds of $506,000 from the sale of 506 Units in this specific closing.
Instrument Details: Each Unit consists of one share of Series C 5.5% Convertible Preferred Stock and two five-year warrants (Series C-1 and Series C-2).
Conversion and Exercise Terms:
- Preferred Stock: Convertible into common stock at an initial price of $4.50 per share.
- Series C-1 Warrants: Exercise price of $4.50 per share.
- Series C-2 Warrants: Exercise price of $7.75 per share.
Dilution Potential: The Preferred Stock in this closing is convertible into 112,446 shares of common stock. The associated Warrants are exercisable for 224,892 shares of common stock.
Placement Agent Compensation: The company paid a commission of 10% of the aggregate sales price plus a 3% non-accountable expense allowance. Additionally, the company issued warrants to the placement agent for up to 22,489 shares at $4.50 and 11,244 shares at $7.75.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
This transaction represents the seventh closing of an ongoing offering of Units. Previous closings disclosed in prior 8-K filings (April through October 2016) involved the sale of 5,322.9 Units in total. The terms of the Preferred Stock and Warrants in this closing are identical to those in the prior issuances.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the capital raise and does not provide specific forward-looking guidance, operational outlook, or management commentary on business performance.
Risks and Contingencies: The securities were sold without registration under the Securities Act of 1933, relying on an exemption under Section 4(a)(2) for accredited investors. The placement agent warrants include full ratchet anti-dilution protection and cashless exercise options, which may impact future share counts.
Investor Verification Checklist
- Verify the total capital raised across all seven closings of this offering to assess the full funding round size.
- Confirm the current outstanding share count and the potential dilution impact of the 112,446 convertible shares and 224,892 warrant shares from this closing alone.
- Review the "Prior 8-Ks" referenced in the filing to understand the cumulative terms of the Series C Preferred Stock and the total number of units issued previously.
- Assess the impact of the placement agent's full ratchet anti-dilution protection on future equity valuations.
- Clarify the company's current cash position and burn rate, as this filing does not disclose liquidity metrics.